Caas Capital Management LP Humanigen, Inc Transaction History

Caas Capital Management LP

  • $836 Million
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 12, 2021
SELL
$7.97 - $21.66 $247,484 - $672,586
-31,052 Closed
0 $0
Q3 2020

Nov 09, 2020
BUY
$8.0 - $28.5 $248,416 - $884,982
31,052 New
31,052 $330,000

Others Institutions Holding HGEN

# of Institutions
4
Shares Held
558K
Call Options Held
0
Put Options Held
0
View Full List

About HUMANIGEN, INC

HGEN Quotes by TradingView
  • Ticker HGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,661,000
  • Description
  • Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...
More about HGEN
Track This Portfolio

Track Caas Capital Management LP Portfolio

Follow Caas Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Caas Capital Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email